Clinical Trials
18 trialsNCT07550855 2026-04-24
FLOURISH
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
NCT07321652 2026-01-07
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Alliance for Clinical Trials in Oncology
Phase 3 Not yet recruiting
NCT07299331 2025-12-23
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
Zhengzhou University
Phase NA Not yet recruiting
NCT06547866 2025-11-26
WAZABI
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT06665217 2025-08-14
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT07012980 2025-06-10
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07003464 2025-06-04
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
The First Hospital of Jilin University
Phase 2 Not yet recruiting
NCT06973811 2025-05-20
ZR-MTX
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT06942507 2025-04-30
BRZ-WM
Peking Union Medical College Hospital
Phase NA Not yet recruiting
NCT06646666 2024-11-01
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06669143 2024-11-01
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06646211 2024-10-17
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06549335 2024-10-15
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06427213 2024-05-23
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06367374 2024-04-16
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT06255704 2024-02-13
Z+RCHOP/RDHAP
Shanxi Province Cancer Hospital
Phase 2 Not yet recruiting
NCT05596097 2022-10-27
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
LanZhou University
Phase 2 Not yet recruiting